肺腺癌患者癌组织中SMC2的表达及其对预后影响的分析

Analysis of SMC2 expression in lung adenocarcinoma tumor tissues and its prognostic implications

目的探讨SMC2在肺腺癌中的表达情况以及其在临床预后中的价值。方法收集我院207例肺腺癌患者的石蜡包埋组织样本进行免疫组织化学分析,检测SMC2蛋白的表达情况。利用TCGA数据库分析肺腺癌样本及癌旁组织SMC2 mRNA的表达数据。分析且探讨SMC表达与临床分期和生存预后的关系。结果免疫组化分析确认,肺腺癌组织中SMC2蛋白高表达,且与肿瘤分期密切相关,是不良预后的危险因素。肺腺癌组织中SMC2 mRNA表达亦显著增高且高于癌旁正常组织,并与肿瘤的TNM分期正相关;Kaplan-Meier分析显示SMC2 mRNA表达较高的患者生存期明显较短。结论SMC2高表达可能作为肺腺癌患者的危险预测因子,为肺腺癌的诊断和治疗提供了新的研究方向。

Objective To investigate the expression of SMC2 in lung adenocarcinoma and its clinical prognostic value.Methods Paraffin-embedded tissue samples from 207 patients with lung adenocarcinoma were collected for immunohistochemical analysis to examine the expression of SMC2 protein.The expression data of SMC2 mRNA in lung adenocarcinoma samples and adjacent normal tissues were analyzed using the TCGA database.The relationship between SMC2 expression and clinical staging as well as survival prognosis was analyzed.Results Immunohistochemical analysis confirmed the high expression of SMC2 protein in lung adenocarcinoma tissues was closely associated with tumor staging and indicated poor prognosis.Moreover,SMC2 mRNA expression was significantly elevated in lung adenocarcinoma tissues compared to adjacent normal tissues and positively correlated with the TNM staging of the tumors.Kaplan-Meier analysis demonstrated that patients with higher SMC2 mRNA expression had significantly shorter overall survival.Conclusion High expression of SMC2 may serve as a potential prognostic factor for lung adenocarcinoma patients,providing a new research direction for the diagnosis and treatment of this disease.